![Platinum drugs are off the shortage list, but the underlying problem is unsolved FDA’s Califf: “We have a market failure due to unwillingness of health systems and cancer centers to pay a fair price.”](https://cdn.cancerletter.com/media/2024/07/19144029/50-29-4x3-1.jpg)
![Platinum drugs are off the shortage list, but the underlying problem is unsolved FDA’s Califf: “We have a market failure due to unwillingness of health systems and cancer centers to pay a fair price.”](https://cdn.cancerletter.com/media/2024/07/19144029/50-29-4x3-1.jpg)
Cover Story
More than a year after a catastrophic shortage of platinum-based chemotherapy drugs swept through the U.S., FDA on June 28 officially removed carboplatin and cisplatin from the drug shortage list.
In Brief
![In Brief](https://cdn.cancerletter.com/media/2019/05/03155624/in-brief-3.jpg)
![In Brief](https://cdn.cancerletter.com/media/2019/05/03155624/in-brief-3.jpg)
Clinical Roundup
![Clinical Roundup](https://cdn.cancerletter.com/media/2019/05/03161627/clinical_roundup.jpg)
![Clinical Roundup](https://cdn.cancerletter.com/media/2019/05/03161627/clinical_roundup.jpg)
Trending Stories
- How Beth Carner went from six weeks left to live with stage 4 colon cancer to complete remission
- Infections are a major cause of death in patients treated with CAR T-cell therapy
Meta-analysis focused on causes of death, excluding relapse, recurrence - Robert Gallo named founding director of Microbial Oncology Program at TGH Cancer Institute
- In 1971, Chris Lundy had minute odds of survival. He is now the longest living BMT recipient at the Hutch
- What are you reading in 2023?
- Lei Zheng named executive director of Mays Cancer Center